Takeda Oncology
Sascha Haverfield currently serves as the Head of Portfolio Strategy and Operations for the Oncology TAU at Takeda Oncology, where strategic alignment of the R&D portfolio and agile execution of asset strategies are paramount. Previous roles at Takeda included oversight of New Product Planning and leadership in Regulatory Affairs for the Plasma-derived Therapies Business Unit. Notably, during tenure at Shire, Sascha held the position of Group Vice President, leading global regulatory strategies across multiple therapeutic areas. A seasoned professional in regulatory affairs, Sascha's earlier experience includes impactful roles at PhRMA, Abbott Laboratories, and deCODE genetics, coupled with a strong academic background featuring a Doctorate from the University of Oxford.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.